Skip to content

Other ways to search: Events Calendar | UTHSC News

Leadership

James CarsonJames Carson, PhD, FACSM
Executive Director, TennIRM

James Carson, PhD, serves as the executive director for TennIRM at UTHSC. He is a professor in the Department of Physical Therapy, senior associate dean for Research and Graduate Studies in the College of Health Professions, and chief of the Division of Rehabilitation Sciences. He received his PhD degree from Ohio State University. His training includes a National Institutes of Health-funded post-doctoral research in physiology at the University of Texas Health Science Center-Houston and cell biology at Baylor College of Medicine in Houston, Texas, funded through the Huffington Center on Aging. Following his post-doctoral work, Dr. Carson was appointed to the faculty at the University of South Carolina and established a program of muscle biology research for 19 years. At the University of South Carolina, he served as associate director for the Center for Colon Cancer, department chair, and director of Graduate Studies. Dr. Carson’s research employs molecular biology techniques with in vivo and in vitro models to examine skeletal muscle metabolic regulation with cancer, regeneration, and inflammation. The NIH has funded him as PI for over 16 years. Additionally, he has served as a co-PI on several research projects and co-I on many funded projects with junior investigators. He has over 115 peer-reviewed publications related to muscle physiology/biology, and his research has received over 8,000 citations. Dr. Carson is a standing panel member for both NIH and VA grant application reviews. He also serves as associate editor for three journals. As department chair, associate Cancer Center director, and associate dean for Research, he has been extensively involved in faculty mentorship in research and doctoral program development.

James KangY. James Kang, PhD
Chief Scientist, TennIRM

Dr. Kang is a UTHSC professor and Chief Scientist, Tennessee Institute of Regenerative Medicine, and professor and Director of the Regenerative Medicine Research Center at Sichuan University West China Medical College. He also is the president and CEO of Sichuan 3D Bio-printing Research and Technology Institute; the director of Sichuan Regenerative Medicine Research and Technology Center; the editor-in-chief of the journals Cardiovascular Toxicology and Regenerative Medicine Research; and the editor of the book series of Methods in Pharmacology and Toxicology. Dr. Kang received his PhD in Toxicology and Zoology at Iowa State University in 1989 and completed postdoctoral training in Biochemistry and Molecular Biology at Cornell University Medical Center in 1990. He was assistant professor of Pharmacology and Toxicology, University of North Dakota School of Medicine (1991-1996); associate professor of Medicine, Pharmacology and Toxicology and University Scholar, University of Louisville School of Medicine (1996-2001); professor and Distinguished University Scholar (2001-2017). He served several NIH study sections from 1997 to 2006, and other federal agencies including USDA, US-EPA and US-Veterans Administrations from 1996 to 2005. He was elected to Fellow of the Academy of Toxicological Sciences in 2001.Dr. Kang’s research interests are in regenerative medicine, focusing on 3D bio-printing and cardiovascular regeneration, as well as mineral manipulation of cardiovascular disease, liver fibrosis and cirrhosis, and non-human primate models of human diseases. He is also an entrepreneur, and involved in several business operations, including the founder and president of Innolife Co, founder and past-CEO of Revotek, and chief scientist of Tesly Co. His business is involved in commercialization of regenerative medicine technologies. 

Nov 28, 2022